Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03121014 Background | Apr 2017 → Apr 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | University of Illinois at Chicago | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03121014 ↗ |
| Modality | Protein / enzyme biologic | “rabbit anti-thymocyte globulin” PMID 40534485 ↗ Jun 2025 |
| Route | Intravenous | “0.5 mg/kg IV on day -3” NCT03121014 ↗ |